Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021

Lin, Kuan‐Yin; Hsieh, Ming‐Ju; Chang, Shih‐Ying; Ieong, Si‐Man; Cheng, Chien-Yu; Sheng, Wang‐Huei; Chang, Shan‐Chwen

doi:10.1016/j.jfma.2022.08.017

Cited by 5 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of autoimmune diagnosis, studies included adult-onset Still’s disease [ 57 , 61 , 89 , 95 ], antiphospholipid syndrome [ 33 , 47 , 69 , 72 , 74 , 75 , 88 , 89 , 94 , 96 , 102 ], autoimmune encephalitis [ 40 , 52 , 60 ], autoimmune hepatitis [ 44 , 56 , 69 , 90 , 97 , 101 ], autoimmune thyroid [ 69 , 96 ], IgG-4-related diseases [ 47 , 69 , 92 , 94 ], interstitial lung disease and systemic autoimmune disease/immune pulmonary disease [ 49 , 69 ], inflammatory bowel disease [ 47 , 50 , 62 , 69 , 71 , 91 , 97 ], inflammatory myopathies/systemic autoimmune myopathy [ 33 , 35 , 36 , 61 , 63 , 69 , 72 , 74 , 75 , 76 , 77 , ...…”

Section: Resultsmentioning

confidence: 99%

“…Autoimmune medications given to the patients included alemtuzumab [ 29 , 34 , 48 , 66 ], abatacept [ 8 , 33 , 35 , 39 , 47 , 57 , 58 , 63 , 72 , 73 , 74 , 75 , 94 , 98 ], anti-CD20/-B cell depleting therapy [ 8 , 29 , 32 , 33 , 34 , 35 , 37 , 39 , 40 , 41 , 43 , 45 , 47 , 48 , 49 , 52 , 53 , 54 , 55 , 57 , 60 , 62 , 63 , 64 , 65 , 66 , 72 , 74 , 75 , 87 , 89 , 92 , 94 , 96 , 97 , …”

Section: Resultsmentioning

confidence: 99%

“…A study of patients with SLE who had been given the Pfizer vaccination found that mycophenolate and methotrexate treatment were associated with a drastically diminished BNT162b2 antibody response [ 68 ]. Another study on the Moderna and Vaxzevria vaccines showed that individuals given hydroxychloroquine, low-dose steroid, methotrexate, and/or sulfasalazine therapy had significantly lower anti-SARS-CoV-2 spike IgG titers than those who were not on these therapies [ 96 ].…”

Section: Resultsmentioning

confidence: 99%

“…All studies concerned adult participants (the majority of participants were >18 years of age), and only one study also involved pediatric participants [91]. Sixty-six studies included participants who had only had a primary dose vaccine [8,29,30,[35][36][37][38][39]41,[82][83][84][85][86][87][88][89][90][91][92][93][97][98][99][100][101][102][103], whereas in ten studies participants had had a booster dose vaccine [31][32][33][34]40,42,81,[94][95][96].…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Autoimmune medications given to the patients included alemtuzumab [29,34,48,66], abatacept [8,33,35,39,47,57,58,63,[72][73][74][75]94,98], anti-CD20/-B cell depleting therapy [8,29,[32][33][34][35]37,[39][40][41]43,45,[47][48][49][52][53][54][55]57,60,[62][63][64][65][66]72,74,75,87,89,92,94,[96]…”

Section: Study Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis

Widhani,

Hasibuan,

Rismawati

et al. 2023

Vaccines

View full text Add to dashboard Cite

Patients with autoimmune diseases are among the susceptible groups to COVID-19 infection because of the complexity of their conditions and the side effects of the immunosuppressive drugs used to treat them. They might show impaired immunogenicity to COVID-19 vaccines and have a higher risk of developing COVID-19. Using a systematic review and meta-analysis, this research sought to summarize the evidence on COVID-19 vaccine efficacy, immunogenicity, and safety in patients with autoimmune diseases following predefined eligibility criteria. Research articles were obtained from an initial search up to 26 September 2022 from PubMed, Embase, EBSCOhost, ProQuest, MedRxiv, bioRxiv, SSRN, EuroPMC, and the Cochrane Center of Randomized Controlled Trials (CCRCT). Of 76 eligible studies obtained, 29, 54, and 38 studies were included in systematic reviews of efficacy, immunogenicity, and safety, respectively, and 6, 18, and 4 studies were included in meta-analyses for efficacy, immunogenicity, and safety, respectively. From the meta-analyses, patients with autoimmune diseases showed more frequent breakthrough COVID-19 infections and lower total antibody (TAb) titers, IgG seroconversion, and neutralizing antibodies after inactivated COVID-19 vaccination compared with healthy controls. They also had more local and systemic adverse events after the first dose of inactivated vaccination compared with healthy controls. After COVID-19 mRNA vaccination, patients with autoimmune diseases had lower TAb titers and IgG seroconversion compared with healthy controls.

show abstract